Igmesine – Knowledge and References

Explore chapters and articles related to this topic

Development of New Treatment Options for Depression

Published in Siegfried Kasper, Johan A. den Boer, J. M. Ad Sitsen, Handbook of Depression and Anxiety, 2003

Sigma antagonists were originally studied in schizophrenia, with relatively limited efficacy on positive symptoms. Recently, one such compound, igmesine, has begun to be studied in major depression. Results are not yet available. Still, sigma antagonists represent a novel approach to antidepressant therapy [79]. Recently, deramciclane, a specific-acting serotonergic antidepressant, has come under investigation [52,69]. The other novel compound studied in animal experiments is agomelatin [88].

Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders

View Article

Journal Information

Published in Expert Opinion on Drug Discovery, 2021

Tangui Maurice

In a different indication, but with a result highly illustrative for our talk, igmesine was evaluated in a multicentric phase II clinical trial for the treatment of depression [116]. Two groups were treated with either 25 mg or 100 mg daily regimen of igmesine and compared to placebo or fluoxetine 20 mg. The total Hamilton depression rating scale (HAM-D) score showed a significant beneficial effect with the low dose (25 mg) igmesine in an out-patient sub-group compared to placebo. The higher igmesine dose (100 mg) failed to show a significant effect [116].